Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to myelofibrosis

fibrosis of the bone marrow

Related Words

References in periodicals archive ?
Results from PERSIST-1 add to the growing body of data showing the potential for pacritinib to address an unmet medical need that currently exists for patients with myelofibrosis, particularly patients with severely low platelet counts that result either from their disease or as a side effect from current treatment," said James A.
Results from a Phase 2 study of pacritinib in patients with myelofibrosis were published in the journal Blood.
Gilead is also conducting Phase 2 clinical trials of simtuzumab (formerly referred to as GS-6624), an investigational monoclonal antibody (mAb) candidate targeting the human lysyl oxidase-like 2 (LOXL2) protein, in myelofibrosis, colorectal cancer, pancreatic cancer and certain fibrotic diseases.
15] defined a syndrome of PAIMF, highlighting the features of a lack of association with a well-defined autoimmune syndrome, no splenomegaly, presence of autoantibodies and the absence of a disorder known to cause myelofibrosis.
The long-term data for Jakafi continue to demonstrate tangible benefits for patients with myelofibrosis, including better management of this progressive and debilitating disease and an apparent improvement in overall survival," stated Srdan Verstovsek, M.
A snapshot of the global therapeutic scenario for Post-polycythemia vera myelofibrosis (PPV-MF).
20 as Myelofibrosis Awareness Day to connect organizations, doctors and individuals affected by MF to ensure that patients and their families have the necessary information, support and resources to better manage this disease," stated Ann Brazeau, chairperson of the MPN Coalition and Vice President of Development of the MPN Research Foundation.
Decision Follows Pre-NDA Meeting with the FDA to Request Accelerated Approval for Patients with Myelofibrosis and Low Platelet Counts -
Incyte Corporation (Nasdaq: INCY) today announced that its strategic collaborator, Novartis, received approval from the European Commission for Jakavi([R]) (INC424, ruxolitinib), an oral JAK 1 and JAK 2 inhibitor discovered by Incyte, for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.
Positive Phase 3 Results for Pacritinib Demonstrating Significant Clinical Benefit in Patients with Myelofibrosis Presented at ASCO and EHA -
This clinical trial report, Myelofibrosis Global Clinical Trials Review, H2, 2012" provides data on the Myelofibrosis clinical trial scenario.
His recent launch experience, particularly in blood-related cancers, will be of great value to the ongoing commercialization of PIXUVRI in the EU as well as the future advancement of our pipeline, including the potential launch of pacritinib for patients with myelofibrosis.
Data from an ongoing trial suggest a dosing strategy with Jakafi that may be efficacious and well-tolerated in myelofibrosis patients with low platelet counts
Among other complications, most patients with myelofibrosis present with enlarged spleens (splenomegaly), as well as many other potentially devastating physical symptoms such as abdominal discomfort, bone pain, feeling full after eating little, severe itching, night sweats, and extreme fatigue.